Back to search

Article

A First in Human Trial to Evaluate the Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years

2022-12-29

Abstract excerpt

<h4>Background</h4> With enormous morbidity and mortality induced by respiratory syncytial virus (RSV) infection among infants and the elderly, vaccines against RSV infection are in huge market demand. <h4>Methods</h4> We conducted a First-in-human (FIH), randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety and immunogenicity response of the rRSV vaccine (BARS13) in healthy adu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e807cf74-5eef-5bb7-a693-7916f238b5e9
DOI
10.1101/2022.12.27.22283128
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A First in Human Trial to Evaluate the Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 YearsDOI 10.1101/2022.12.27.22283128
A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of AgeSemantic proximity
Respiratory Syncytial Virus Vaccines: Analysis of the Pre-Marketing Clinical Trial for Immunogenicity in the Population over 50 Years of AgeSemantic proximity
The efficacy and safety of an intranasal spray COVID-19 vaccine in a randomized double-blind placebo-controlled phase Ⅲ trial during Omicron periodSemantic proximity
Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized AdultsSemantic proximity
The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trialSemantic proximity
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trialSemantic proximity
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenSemantic proximity
Live-Attenuated Intranasal RSV Vaccine in Infants and ToddlersSemantic proximity
Immunogenicity and Safety of Serum-Free Rabies Vaccine (Vero Cell) for Human Use, Freeze-Dried with Different Immunization Schedules: A Randomized, Double-Blind, Active-Controlled Phase Ⅰ/Ⅲ Clinical TrialSemantic proximity
Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)Semantic proximity
Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in RussiaSemantic proximity
Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial VirusSemantic proximity
Select a neighboring publication to make it the new centre.